CYRX achieved a dramatic turnaround with net income swinging from -$114.8M to +$78.3M while cash increased 453% to $250.5M, likely driven by the CRYOPDP divestiture.
This represents a fundamental transformation of the company's financial position, moving from significant losses to profitability while dramatically strengthening the balance sheet. The massive cash increase combined with profitability suggests a major asset sale or financing event that has repositioned the company for growth, particularly given their stated focus on the rapidly expanding cell and gene therapy market.
CYRX experienced a complete financial turnaround with net income improving by $193M to achieve profitability of $78.3M, while cash surged 453% to $250.5M, indicating a major divestiture or capital event. Operating performance improved significantly with operating losses narrowing 72% and SG&A expenses declining 31%, though the company remains operationally unprofitable at -$36.8M. The dramatic increase in current liabilities to $219M alongside the cash boost suggests transaction-related obligations, but the overall picture shows a company that has monetized assets to achieve near-term profitability while maintaining a strong liquidity position.
Cash position surged 453.1% — strong cash generation or capital raise providing significant financial cushion.
Debt increased 297.9% — substantial leverage increase; assess whether deployed for growth or covering losses.
Current liabilities surged 239.2% — significant near-term obligations; verify ability to meet short-term debt.
Net income grew 168.2% — bottom-line growth signals improving overall business health.
Buyback activity reduced 73.6% — capital being redeployed elsewhere or cash conservation underway.
Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.
Operating cash flow surged 47.4% — exceptional cash generation, highest quality earnings signal.
Current assets grew 39.4% — improving short-term liquidity or inventory/receivables build.
SG&A reduced 31% — improved cost efficiency or headcount reduction improving operating margins.
Receivables declined — improved collection efficiency or conservative revenue recognition.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →